Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection.

Publication Type:

Journal Article


Gastroenterology, Volume 138, Issue 2, p.671-81, 681.e1-2 (2010)


2010, Antioxidants, Case-Control Studies, Cell Line, Cell Proliferation, Cells, Cultured, Center-Authored Paper, Cytokines, Dose-Response Relationship, Drug, Hepacivirus, Hepatitis C, Humans, interferon-gamma, Interleukin-2, Jurkat Cells, Leukocytes, Mononuclear, Silymarin, T-Lymphocytes, Tumor Necrosis Factor-alpha, Vaccine and Infectious Disease Division


Silymarin, an extract from the seeds of the milk thistle plant Silybum marianum, has been used for centuries for the treatment of chronic liver diseases. Despite common use by patients with hepatitis C in the United States, its clinical efficacy remains uncertain. The goal of this study was to determine whether silymarin has in vitro effects on immune function that might have implications for its potential effect on hepatitis C virus (HCV)-induced liver disease.